Absci (ABSI) EBITDA Margin (2020 - 2026)
Absci (ABSI) reported EBITDA Margin of 14346.98% for Q1 2026, down 1199507.0% on a YoY basis from N/an in Q1 2025, and down 200.43% sequentially from 4775.54% in Q4 2025.
Absci (ABSI) EBITDA Margin (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of EBITDA Margin data on file, last reported at 14346.98% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 1199507.0% year-over-year to 14346.98%; the trailing twelve-month figure through Mar 2026 stood at 6722.98% (down 437368.0% YoY), and the FY2025 full-year result was 4297.04%, down 189545.0% from the prior year.
- EBITDA Margin declined to 14346.98% in Q1 2026, from 4775.54% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1276.74% in Q2 2023 to a low of 14346.98% in Q1 2026.
- A 5-year average of 4938.73% and a median of 4477.29% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin soared 652707 bps in 2022 and slumped 1199507 bps in 2026, its largest moves.
- Tracing ABSI's EBITDA Margin over 5 years: stood at 6222.12% in 2022, then fell by 18 bps to 7319.23% in 2023, then jumped by 39 bps to 4477.29% in 2024, then retreated by 7 bps to 4775.54% in 2025, then slumped by 200 bps to 14346.98% in 2026.
- Business Quant data shows ABSI's EBITDA Margin at 14346.98% in Q1 2026, 4775.54% in Q4 2025, and 7977.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | -14,346.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,346.98% |
| Dec 31, 2025 | -4,775.54% |
| Sep 30, 2025 | -7,977.25% |
| Jun 30, 2025 | -5,293.93% |
| Mar 31, 2025 | -2,351.91% |
| Dec 31, 2024 | -4,477.29% |
| Sep 30, 2024 | -1,698.71% |
| Jun 30, 2024 | -2,104.02% |
| Mar 31, 2024 | -2,616.70% |
| Dec 31, 2023 | -7,319.23% |
| Sep 30, 2023 | -3,132.12% |
| Jun 30, 2023 | -1,276.74% |
| Mar 31, 2023 | -1,929.47% |
| Dec 31, 2022 | -6,222.12% |
| Sep 30, 2022 | -7,662.19% |
| Jun 30, 2022 | -2,882.93% |
| Mar 31, 2022 | -7,891.23% |
| Dec 31, 2021 | 1,221.78% |
| Sep 30, 2021 | -14,189.26% |
| Jun 30, 2021 | -2,292.86% |